Skip to main content

Table 2 Raynaud's phenomenon and autoantibodies in scleroderma patients

From: Atypical clinical presentation of a subset of patients with anti-RNA polymerase III - non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining

  RNAP III
(n= 18)
Topo I
(n= 24)
ACA
(n= 15)
U3RNP
(n= 9)
Th/To
(n= 8)
Prevalence of RP 94% (16/17) 96% (23/24) 100% (15/15) 100% (9/9) 87% (7/8)
Absence of RP at first visit
(in RP positive cases)
18% (3/16)1, 2 0% (0/23)2 0% (0/15) 0% (0/9) 0% (0/7)
Scleroderma prior to RP 31% (5/16)3, 4, 5 4% (1/23)3 0% (0/15)4 0% (0/9) 0% (0/8)
RP to scleroderma > 1 y 25% (4/16) 6 53% (10/19) 58% (7/12) 50% (4/8) 57% (4/7)
RP to scleroderma
(year, mean ± SD)
1.5 ± 5.37, 8
(0.2 ± 1.2)9
4.1 ± 8.9 5.7 ± 5.87 1.1 ± 1.7 2.6 ± 3.4
  1. RP, Raynaud's phenomenon
  2. 1 RNAP III vs others, P = 0.01; 2 RNAP III vs Topo I, P = 0.07; 3 RNAP III vs Topo I, P = 0.03; 4 RNAP III vs ACA, P = 0.04; 5 RNAP III vs others, P = 0.002; 6 RNAP III vs others, P = 0.08; 7 RNAP III vs ACA, P = 0.03; 8 RNAP III vs others, P = 0.03; 9 Value after excluding an outlier that has 21 years interval between RP to scleroderma.
  3. 1-6 by Fisher's exact test, 7,8 by Mann-Whitney